Biohaven Ltd.
opakalim
Epilepsy
Resolved
7days ago
Phase 3 readout · Jun 30, 2026
What's at stake
Phase 3 trial results for opakalim in Epilepsy are due Jun 30, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 16h ago
“Pivotal results for opakalim in the treatment of focal epilepsy are expected in the second half of 2026.”